Pericyte progenitors from peripheral blood
US-9809798-B2 · Nov 7, 2017 · US
Lung perfusion solution, and use thereof for the ex-vivo preservation of a mammalian lung
US12465045B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12465045-B2 |
| Application number | US-202117541511-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2021 |
| Priority date | Apr 8, 2015 |
| Publication date | Nov 11, 2025 |
| Grant date | Nov 11, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.
First claim
Opening claim text (preview).
What is claimed is: 1 . An organ perfusion solution comprising: a base solution comprising a physiological mixture of electrolytes and buffers; and 3.5-5.5% w/v a first macromolecule having a molecular weight of 40-100 kDa and an amount of a second, high molecular weight, macromolecule having a molecular weight of 350-600 kDa to adjust the relative viscosity of the organ perfusion solution to 2.1-2.7. 2 . The organ perfusion solution of claim 1 , wherein the organ perfusion solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5. 3 . The organ perfusion solution of claim 1 , wherein the organ perfusion solution solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5 and in which the second, high molecular weight, macromolecule has a molecular weight of 350-450 kDa. 4 . The organ perfusion solution of claim 1 , wherein the second, high molecular weight, macromolecule is a branched polysaccharide-based polymer. 5 . The organ perfusion solution of claim 1 , wherein the second, high molecular weight, macromolecule is non-ionic. 6 . The organ perfusion solution of claim 1 , wherein the second, high molecular weight, macromolecule is a FICOLL PM400. 7 . The organ perfusion solution of claim 1 , wherein the second, high molecular weight, macromolecule is provided in an amount of 2-5% w/v. 8 . The organ perfusion solution of claim 1 , wherein the first macromolecule is a molecule having a molecular weight of 60-80 KDa. 9 . The organ perfusion solution of claim 1 , wherein the first macromolecule is a polysaccharide-based polymer. 10 . The organ perfusion solution of claim 1 , wherein the first macromolecule is non-ionic. 11 . The organ perfusion solution of claim 1 , wherein the first molecular weight macromolecule is a FICOLL PM70. 12 . The organ perfusion solution of claim 1 , wherein the first macromolecule has a molecular weight of 60-80 KDa; and the organ perfusion solution comprises 2-5% w/v of the second macromolecule. 13 . A method of perfusing an organ ex vivo comprising a step of perfusing an organ perfusion solution of claim 1 , through the organ. 14 . An organ perfusion solution comprising a base solution comprising a physiological mixture of electrolytes and buffers; and 3.5-5.5% w/v FICOLL PM70, and an amount of FICOLL PM400 to adjust the relative viscosity of the organ perfusion solution to 2.1-2.7. 15 . The method of claim 13 , wherein the organ perfusion solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the organ perfusion solution to about 2.5. 16 . The method of claim 13 , wherein the organ perfusion solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the organ perfusion solution to about 2.5 and in which the second, high molecular weight, macromolecule has a molecular weight of 350-450 kDa. 17 . The method of claim 13 , wherein the first macromolecule has a molecular weight of 60-80 KDa; and the organ perfusion solution comprises 2-5% w/v of the second macromolecule. 18 . A method of perfusing an organ ex vivo comprising a step of perfusing an organ perfusion solution of claim 14 , through the organ. 19 . The method of claim 13 , wherein the organ is selected from a lung, a heart, a kidney and a liver.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12465045B2 cover?
- A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.
- Who is the assignee on this patent?
- Univ College Dublin Nat Univ Ireland Dublin
- What technology area does this patent fall under?
- Primary CPC classification A01N1/126. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).